$BIOLQ
BIOLASE, INC

2019 Q3 Form 10-Q Financial Statement

#000156459019042402 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q4 2018 Q3
Revenue $8.646M $13.05M $10.94M
YoY Change -20.94% 3.33% 1.2%
Cost Of Revenue $5.677M $7.430M $6.995M
YoY Change -18.84% -17.63% -12.01%
Gross Profit $2.969M $5.610M $3.941M
YoY Change -24.66% 55.4% 37.8%
Gross Profit Margin 34.34% 42.99% 36.04%
Selling, General & Admin $6.725M $8.160M $7.170M
YoY Change -6.21% 26.71% 19.1%
% of Gross Profit 226.51% 145.45% 181.93%
Research & Development $1.126M $1.280M $1.280M
YoY Change -12.03% -7.91% -20.0%
% of Gross Profit 37.93% 22.82% 32.48%
Depreciation & Amortization $220.0K $240.0K $200.0K
YoY Change 10.0% -22.58% -35.48%
% of Gross Profit 7.41% 4.28% 5.07%
Operating Expenses $7.851M $9.440M $8.450M
YoY Change -7.09% 20.56% 10.89%
Operating Profit -$4.882M -$3.830M -$4.509M
YoY Change 8.27% -9.24% -5.27%
Interest Expense -$551.0K -$440.0K -$110.0K
YoY Change 400.91% -331.58% -1200.0%
% of Operating Profit
Other Income/Expense, Net -$570.0K
YoY Change
Pretax Income -$5.452M -$6.950M -$4.616M
YoY Change 18.11% 53.08% 0.85%
Income Tax $26.00K $570.0K $50.00K
% Of Pretax Income
Net Earnings -$5.478M -$6.920M -$4.670M
YoY Change 17.3% 80.21% 1.3%
Net Earnings / Revenue -63.36% -53.03% -42.7%
Basic Earnings Per Share -$0.25 -$0.23
Diluted Earnings Per Share -$0.25 -$333.7K -$0.23
COMMON SHARES
Basic Shares Outstanding 21.90M 20.65M 20.61M
Diluted Shares Outstanding 21.90M 20.61M

Balance Sheet

Concept 2019 Q3 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.090M $8.040M $2.240M
YoY Change -6.7% -30.99% -49.66%
Cash & Equivalents $2.091M $8.044M $2.440M
Short-Term Investments
Other Short-Term Assets $1.190M $1.900M $970.0K
YoY Change 22.68% -4.04% -34.46%
Inventory $11.54M $12.25M $13.42M
Prepaid Expenses
Receivables $8.474M $11.11M $11.40M
Other Receivables $0.00 $51.00K $0.00
Total Short-Term Assets $23.29M $33.31M $28.03M
YoY Change -16.91% -7.61% -5.75%
LONG-TERM ASSETS
Property, Plant & Equipment $1.340M $1.975M $2.930M
YoY Change -54.27% -46.24% -32.64%
Goodwill $2.926M $2.926M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $718.0K $308.0K $370.0K
YoY Change 94.05% -7.78% 8.82%
Total Long-Term Assets $4.984M $5.209M $6.230M
YoY Change -20.0% -24.88% -18.13%
TOTAL ASSETS
Total Short-Term Assets $23.29M $33.31M $28.03M
Total Long-Term Assets $4.984M $5.209M $6.230M
Total Assets $28.27M $38.52M $34.26M
YoY Change -17.48% -10.39% -8.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.604M $5.953M $7.570M
YoY Change -12.76% 16.5% -1.43%
Accrued Expenses $4.950M $7.538M $4.750M
YoY Change 4.21% 60.72% 19.95%
Deferred Revenue $2.512M $2.476M $2.263M
YoY Change 11.0% -5.68%
Short-Term Debt $0.00 $0.00 $1.500M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.07M $15.97M $17.25M
YoY Change -18.46% 19.42% 14.77%
LONG-TERM LIABILITIES
Long-Term Debt $13.36M $10.84M $50.00K
YoY Change 26612.0%
Other Long-Term Liabilities $1.145M $100.0K $510.0K
YoY Change 124.51% -40.83% 59.38%
Total Long-Term Liabilities $14.50M $10.94M $560.0K
YoY Change 2489.46% 6371.01% 75.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.07M $15.97M $17.25M
Total Long-Term Liabilities $14.50M $10.94M $560.0K
Total Liabilities $29.34M $27.43M $17.92M
YoY Change 63.72% 99.85% 10.69%
SHAREHOLDERS EQUITY
Retained Earnings -$231.0M -$216.7M
YoY Change 11.02%
Common Stock $230.7M $228.5M
YoY Change 1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.066M $11.09M $16.34M
YoY Change
Total Liabilities & Shareholders Equity $28.27M $38.52M $34.26M
YoY Change -17.48% -10.39% -8.27%

Cashflow Statement

Concept 2019 Q3 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$5.478M -$6.920M -$4.670M
YoY Change 17.3% 80.21% 1.3%
Depreciation, Depletion And Amortization $220.0K $240.0K $200.0K
YoY Change 10.0% -22.58% -35.48%
Cash From Operating Activities -$1.440M -$3.560M -$2.240M
YoY Change -35.71% -16.24% -31.08%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$450.0K $0.00
YoY Change -662.5% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $40.00K
YoY Change
Cash From Investing Activities -$10.00K -$450.0K $40.00K
YoY Change -125.0% -662.5% -121.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -50.00K 10.01M 1.500M
YoY Change -103.33% -11.81% -1600.0%
NET CHANGE
Cash From Operating Activities -1.440M -3.560M -2.240M
Cash From Investing Activities -10.00K -450.0K 40.00K
Cash From Financing Activities -50.00K 10.01M 1.500M
Net Change In Cash -1.500M 6.000M -700.0K
YoY Change 114.29% -16.43% -80.23%
FREE CASH FLOW
Cash From Operating Activities -$1.440M -$3.560M -$2.240M
Capital Expenditures -$10.00K -$450.0K $0.00
Free Cash Flow -$1.430M -$3.110M -$2.240M
YoY Change -36.16% -28.18% -26.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6604000
dei Entity Shell Company
EntityShellCompany
false
dei Entity Address Address Line1
EntityAddressAddressLine1
4 Cromwell
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Security12b Title
Security12bTitle
Common stock at par value $0.001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2091000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
718000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
308000
CY2019Q3 us-gaap Assets
Assets
28273000
CY2018Q4 us-gaap Assets
Assets
38516000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5953000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4950000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7538000
CY2019Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2512000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2476000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14066000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15967000
CY2019Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
71000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
77000
CY2019Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
701000
CY2018Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
447000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1145000
dei City Area Code
CityAreaCode
949
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Local Phone Number
LocalPhoneNumber
361-1200
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8474000
CY2019Q3 us-gaap Inventory Net
InventoryNet
11537000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
875000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
23289000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1340000
CY2019Q3 us-gaap Goodwill
Goodwill
2926000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27617000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11112000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8044000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2018Q4 us-gaap Inventory Net
InventoryNet
12248000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1591000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
33307000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1975000
CY2018Q4 us-gaap Goodwill
Goodwill
2926000
us-gaap Cost Of Revenue
CostOfRevenue
21828000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33110000
us-gaap Gross Profit
GrossProfit
11282000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13037000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8691000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3927000
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
6995000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21072
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20610000
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20610000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100000
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13356000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10836000
CY2019Q3 us-gaap Liabilities
Liabilities
29339000
CY2018Q4 us-gaap Liabilities
Liabilities
27427000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
22000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
230712000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
228430000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-840000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-670000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230960000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216692000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-1066000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11089000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28273000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38516000
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2084000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
850000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21954
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21072
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21954
CY2019Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
366000
CY2018Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
182000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
798000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8646000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10936000
us-gaap Cost Of Revenue
CostOfRevenue
17746000
us-gaap Gross Profit
GrossProfit
9871000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10665000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8114000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3665000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
20391000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4665000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
3784000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
16337000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
16336000
us-gaap Profit Loss
ProfitLoss
-14268000
us-gaap Profit Loss
ProfitLoss
-14597000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1243000
us-gaap Inventory Write Down
InventoryWriteDown
59000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
103000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
31000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
130000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
43000
us-gaap Share Based Compensation
ShareBasedCompensation
1974000
us-gaap Share Based Compensation
ShareBasedCompensation
1862000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1000
biol Earned Interest Income
EarnedInterestIncome
-2000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1393000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1591000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-711000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1184000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1011000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-940000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1157000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3200000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
36000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-370000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8074000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10590000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
138000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
110000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
36000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
46000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3323000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1823000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2500000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
38000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
87000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
50000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
138000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2416000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1231000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-157000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-23000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5953000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9456000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8356000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11896000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2403000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2440000
us-gaap Interest Paid Net
InterestPaidNet
1315000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
31000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
606000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
biol Non Cash Accrual For Equity Offering Costs
NonCashAccrualForEquityOfferingCosts
191000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
824000
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
236000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
209000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these unaudited consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these unaudited consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the nine-month periods ended September 30, 2019 and 2018, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S.</p>
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.19
CY2018Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.15
CY2018Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
730000
CY2019Q3 biol Working Capital
WorkingCapital
9200000
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2
CY2019Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.77
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.81
CY2018Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.85
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.85
CY2019Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.23
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.15
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2476000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2512000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2476000
CY2019Q3 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
100000
CY2018Q3 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
200000
CY2019Q3 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
566000
CY2019Q3 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1940000
CY2018Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1735000
CY2019Q3 biol Contract With Customer Liability In Deferred Royalties
ContractWithCustomerLiabilityInDeferredRoyalties
6000
CY2018Q4 biol Contract With Customer Liability In Deferred Royalties
ContractWithCustomerLiabilityInDeferredRoyalties
11000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2512000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
500000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
800000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At BIOLASE’s annual meeting of stockholders on May 9, 2018 (the “2018 Annual Meeting”), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended, to effect the Reverse Stock Split and on May 10, 2018, the Company filed an amendment (the “Amendment”) to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of 11:59 p.m. on May 10, 2018. The Amendment also reduced the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares. Prior year share and per share amounts have been adjusted to reflect the impact of the Reverse Stock Split.
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2019Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
800000
CY2018Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
500000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1900000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1900000
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M8D
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
770000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
604000
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.814
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0260
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0290
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1623000
biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
70000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
332000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1359000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1080000
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
124000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.54
biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
2.08
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.27
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.14
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.00
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3D
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
164000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
683000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1008000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5600000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3200000
CY2019Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
3714000
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3590000
CY2019Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1164000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1435000
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6659000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7223000
CY2019Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
800000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1100000
CY2019Q3 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10282000
CY2018Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10153000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9100000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8344000
CY2019Q3 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1182000
CY2018Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1809000
CY2019Q3 us-gaap Land
Land
158000
CY2018Q4 us-gaap Land
Land
166000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1726000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2400000
CY2018Q4 biol Patent Litigation Settlement Current
PatentLitigationSettlementCurrent
1500000
CY2019Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
954000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
861000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
476000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
992000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1044000
CY2019Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
255000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
714000
CY2018Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
328000
CY2019Q3 biol Customer Deposits Liabilities Current
CustomerDepositsLiabilitiesCurrent
82000
CY2018Q4 biol Customer Deposits Liabilities Current
CustomerDepositsLiabilitiesCurrent
21000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
465000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
670000
CY2019Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1498000
CY2018Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1359000
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1308000
CY2019Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
523000
CY2018Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
203000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1145000
CY2019Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1655000
CY2018Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1380000
CY2018Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
375000
CY2018Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1005000
CY2019Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2019Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1644000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1664000
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2100000
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2800000
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10100000
CY2019Q3 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
484000
CY2019Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
1931000
CY2019Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
1848000
CY2019Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
1517000
CY2019Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearFive
1063000
CY2019Q3 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
6843000
CY2019Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1278
us-gaap Operating Lease Payments
OperatingLeasePayments
606000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
803000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
484000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
45000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
529000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
491000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000
CY2019Q3 biol Lease Liability
LeaseLiability
600000
us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
The Company did not enter into any new lease arrangements nor did it have any arrangements that had not commenced.
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
192000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
314000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
23000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
529000
CY2019Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2018Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001564590-19-042402-index-headers.html Edgar Link pending
0001564590-19-042402-index.html Edgar Link pending
0001564590-19-042402.txt Edgar Link pending
0001564590-19-042402-xbrl.zip Edgar Link pending
biol-10q_20190930.htm Edgar Link pending
biol-20190930.xml Edgar Link completed
biol-20190930.xsd Edgar Link pending
biol-20190930_cal.xml Edgar Link unprocessable
biol-20190930_def.xml Edgar Link unprocessable
biol-20190930_lab.xml Edgar Link unprocessable
biol-20190930_pre.xml Edgar Link unprocessable
biol-ex105_258.htm Edgar Link pending
biol-ex311_8.htm Edgar Link pending
biol-ex312_6.htm Edgar Link pending
biol-ex321_9.htm Edgar Link pending
biol-ex322_7.htm Edgar Link pending
biol-ex48_276.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending